Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE RANKIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1922027853
CMS profile
132925
Location
DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,057.34

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,350.89 6
Food and Beverage $706.45 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,526.95 5
Chiesi USA, Inc. $1,399.95 3
AstraZeneca Pharmaceuticals LP $109.14 2
Novo Nordisk Inc $21.30 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE RANKIN

NPI 1922027853 · CMS profile ID 132925

Allopathic & Osteopathic Physicians / Family Medicine

DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1922027853?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $3,057.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $44.1408/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011411643 CMS
AstraZeneca Pharmaceuticals LP $65.0008/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015969923 CMS
ModernaTX, Inc. $233.9007/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056977727 CMS
ModernaTX, Inc. $150.0007/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056977731 CMS
ModernaTX, Inc. $595.4407/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056977735 CMS
ModernaTX, Inc. $325.0007/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056977739 CMS
ModernaTX, Inc. $222.6107/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056977743 CMS
Novo Nordisk Inc $21.3006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001816839 CMS
Chiesi USA, Inc. $1,083.9401/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050862697 CMS
Chiesi USA, Inc. $204.7801/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050862693 CMS
Chiesi USA, Inc. $111.2301/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050862689 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,373.98 97
PY2020 $739.07 44
PY2021 $406.88 25
PY2022 $30.36 2
PY2023 $3,057.34 11
PY2024 $1,612.22 12
PY2025 $249.99 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,755.45 1
PY2025 Principal investigator $4,230,288.19 209
PY2024 Recipient $1,330.16 13
PY2024 Principal investigator $3,187,354.20 327
PY2023 Recipient $893.27 4
PY2023 Principal investigator $6,323,793.75 2,767
PY2022 Recipient $462.00 2
PY2022 Principal investigator $6,941,300.42 589
PY2021 Recipient $15.00 1
PY2021 Principal investigator $10,036,876.19 348
PY2020 Recipient $10,602.17 4
PY2020 Principal investigator $3,545,507.10 644
PY2019 Principal investigator $2,410,610.06 875

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

210 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $79.62 12/31/2025 Non-covered Recipient Entity
Accel Research Sites-DeLand Clinical Research Unit
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1232932986
Principal investigator 1 SANOFI PASTEUR INC. $2,357.20 12/22/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108641
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 12/19/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192680
Principal investigator 1 ModernaTX, Inc. $1,022.58 12/19/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001767
Principal investigator 1 ModernaTX, Inc. $40,285.70 12/19/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001797
Principal investigator 1 ModernaTX, Inc. $6,029.10 12/19/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001803
Principal investigator 1 Eli Lilly and Company $471.45 12/17/2025 Non-covered Recipient Entity
MERIDIEN RESEARCH
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187886718
Principal investigator 1 Janssen Research & Development, LLC $1,622.00 12/12/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192712
Principal investigator 1 Eli Lilly and Company $525.01 12/11/2025 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY INC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187887442
Principal investigator 1 SANOFI PASTEUR INC. $1,682.50 12/09/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108633
Principal investigator 1 SANOFI PASTEUR INC. $4,000.00 12/05/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108626
Principal investigator 1 ABBVIE INC. $8,100.00 12/04/2025 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202526530
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/04/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220997050
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 12/03/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220807075
Principal investigator 1 SANOFI PASTEUR INC. $600.00 12/02/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108618
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220718121
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $1,396.75 12/01/2025 Non-covered Recipient Entity
ACCEL RESEARCH DELAND
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy? No dispute reported 06/30/2026 1214123468
Principal investigator 1 ModernaTX, Inc. $4,090.32 11/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001733
Principal investigator 1 ModernaTX, Inc. $39,134.68 11/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001751
Principal investigator 1 ModernaTX, Inc. $6,373.62 11/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001789
Principal investigator 1 SANOFI PASTEUR INC. $16,500.40 11/21/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108594
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
MERIDIEN RESEARCH
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187886716
Principal investigator 1 Janssen Research & Development, LLC $4,194.00 11/19/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192695
Principal investigator 1 ABBVIE INC. $287.73 11/18/2025 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202524561
Principal investigator 1 SANOFI PASTEUR INC. $8,248.50 11/18/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108587
Principal investigator 1 SANOFI PASTEUR INC. $279,868.17 11/14/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108556
Principal investigator 1 SANOFI PASTEUR INC. $4,497.90 11/14/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108566
Principal investigator 1 SANOFI PASTEUR INC. $2,287.02 11/14/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108571
Principal investigator 1 SANOFI PASTEUR INC. $148.05 11/14/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108583
Principal investigator 1 Janssen Research & Development, LLC $6,899.00 11/07/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192703
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220718119
Principal investigator 1 ModernaTX, Inc. $1,315.60 10/30/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001787
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220718123
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220718125
Principal investigator 1 ModernaTX, Inc. $1,363.44 10/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001761
Principal investigator 1 ModernaTX, Inc. $6,488.46 10/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001831
Principal investigator 1 SANOFI PASTEUR INC. $29,216.74 10/23/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108600
Principal investigator 1 SANOFI PASTEUR INC. $122,574.40 10/23/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108608
Principal investigator 1 ModernaTX, Inc. $4,000.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001721
Principal investigator 1 ModernaTX, Inc. $750.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001807
Principal investigator 1 SANOFI PASTEUR INC. $10,987.56 10/10/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108543
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220718111
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/01/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220718113
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 10/01/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220718115
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Accel Research Sites Deland
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220718117
Principal investigator 1 ModernaTX, Inc. $6,220.50 09/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001729
Principal investigator 1 ModernaTX, Inc. $1,206.60 09/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001753
Principal investigator 1 ModernaTX, Inc. $12,611.82 09/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001827
Principal investigator 1 Janssen Research & Development, LLC $1,345.00 09/19/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192772
Recipient Eli Lilly and Company $1,755.45 09/12/2025 Covered Recipient Physician A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187876319
Principal investigator 1 Janssen Research & Development, LLC $486.00 09/12/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192877
Principal investigator 1 ModernaTX, Inc. $500.00 09/11/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001719
Principal investigator 1 Eli Lilly and Company $275,199.00 09/02/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187892474
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 08/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192113218
Principal investigator 1 GlaxoSmithKline, LLC. $2,200.00 08/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174280
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 08/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174304
Principal investigator 1 ModernaTX, Inc. $12,952.68 08/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001725
Principal investigator 1 ModernaTX, Inc. $16,892.40 08/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001731
Principal investigator 1 ModernaTX, Inc. $833.62 08/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001737
Principal investigator 1 ModernaTX, Inc. $7,062.66 08/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001739
Principal investigator 1 Janssen Research & Development, LLC $4,639.00 08/25/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192765
Principal investigator 1 Janssen Research & Development, LLC $1,858.00 08/22/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192909
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,371.86 08/20/2025 Non-covered Recipient Entity
ACCEL RESEARCH SITES
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185553555
Principal investigator 1 Janssen Research & Development, LLC $1,172.00 08/08/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192794
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $10.66 07/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187893728
Principal investigator 1 ModernaTX, Inc. $1,206.60 07/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001749
Principal investigator 1 ModernaTX, Inc. $681.72 07/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001765
Principal investigator 1 ModernaTX, Inc. $1,703.46 07/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001795
Principal investigator 1 ModernaTX, Inc. $500.00 07/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001805
Principal investigator 1 Janssen Research & Development, LLC $5,029.00 07/23/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192725
Principal investigator 1 ModernaTX, Inc. $182.00 07/23/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001747
Principal investigator 1 ModernaTX, Inc. $1,248.00 07/23/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001821
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 07/21/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH - DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192113212
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 07/21/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH - DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192174293
Principal investigator 1 ABBVIE INC. $400.00 07/08/2025 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202497044
Principal investigator 1 ModernaTX, Inc. $1,491.75 07/07/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990120
Principal investigator 1 ABBVIE INC. $2,239.17 07/02/2025 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202494217
Principal investigator 1 ModernaTX, Inc. $5,112.90 06/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001735
Principal investigator 1 ModernaTX, Inc. $4,826.40 06/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001757
Principal investigator 1 ModernaTX, Inc. $5,856.84 06/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001835
Principal investigator 1 Janssen Research & Development, LLC $586.00 06/25/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192848
Principal investigator 1 Janssen Research & Development, LLC $510.00 06/23/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192757
Principal investigator 1 GlaxoSmithKline, LLC. $3,897.81 06/20/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174456
Principal investigator 1 Janssen Research & Development, LLC $1,732.00 06/20/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192687
Principal investigator 1 Janssen Research & Development, LLC $51,783.00 06/20/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192739
Principal investigator 1 ModernaTX, Inc. $1,667.24 06/18/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001727
Principal investigator 1 ModernaTX, Inc. $51,883.80 06/18/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001771
Principal investigator 1 ModernaTX, Inc. $6,239.64 06/18/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001779
Principal investigator 1 ModernaTX, Inc. $6,135.48 06/18/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001825
Principal investigator 1 SANOFI PASTEUR INC. $600.00 06/16/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108550
Principal investigator 1 SANOFI PASTEUR INC. $1,100.00 06/16/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108562
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 06/16/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108577
Principal investigator 1 SANOFI PASTEUR INC. $3,250.00 06/13/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108498
Principal investigator 1 SANOFI PASTEUR INC. $24,500.00 06/13/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108505
Principal investigator 1 SANOFI PASTEUR INC. $859.10 06/13/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108515
Principal investigator 1 SANOFI PASTEUR INC. $9,984.02 06/13/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108521
Principal investigator 1 SANOFI PASTEUR INC. $3,748.80 06/13/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108526
Principal investigator 1 SANOFI PASTEUR INC. $22,535.40 06/13/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108535
Principal investigator 1 SANOFI PASTEUR INC. $212,517.14 06/12/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108488
Principal investigator 1 ModernaTX, Inc. $2,288.00 06/11/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001785
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 06/09/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192113236
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 06/09/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174296
Principal investigator 1 SANOFI PASTEUR INC. $1,749.44 06/09/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108483
Principal investigator 1 SANOFI PASTEUR INC. $13,700.00 06/06/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108477
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 06/05/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192113228
Principal investigator 1 Janssen Research & Development, LLC $2,294.00 06/02/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192817
Principal investigator 1 SANOFI PASTEUR INC. $600.00 06/02/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108461
Principal investigator 1 SANOFI PASTEUR INC. $1,409.82 06/02/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108467
Principal investigator 1 SANOFI PASTEUR INC. $19,209.60 06/02/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108473
Principal investigator 1 ModernaTX, Inc. $39,817.80 05/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001763
Principal investigator 1 ModernaTX, Inc. $23,178.48 05/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001791
Principal investigator 1 ModernaTX, Inc. $6,947.82 05/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001813
Principal investigator 1 ModernaTX, Inc. $833.62 05/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001829
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 05/28/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108430
Principal investigator 1 SANOFI PASTEUR INC. $12,780.00 05/28/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108435
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 05/28/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108441
Principal investigator 1 GlaxoSmithKline, LLC. $375.69 05/26/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192113222
Principal investigator 1 GlaxoSmithKline, LLC. $2,327.42 05/26/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174278
Principal investigator 1 GlaxoSmithKline, LLC. $4,296.89 05/26/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174284
Principal investigator 1 Novo Nordisk AS $2,750.00 05/23/2025 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1213757257
Principal investigator 1 Novo Nordisk AS $3,366.89 05/23/2025 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1213780569
Principal investigator 1 Janssen Research & Development, LLC $1,616.00 05/20/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192788
Principal investigator 1 SANOFI PASTEUR INC. $1,382.76 05/16/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108395
Principal investigator 1 SANOFI PASTEUR INC. $87,869.60 05/16/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108402
Principal investigator 1 ModernaTX, Inc. $105.00 05/07/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252990122
Principal investigator 1 ModernaTX, Inc. $500.00 05/07/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001769
Principal investigator 1 SANOFI PASTEUR INC. $3,590.18 05/02/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108384
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,500.00 04/30/2025 Non-covered Recipient Entity
ACCEL RESEARCH SITES
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185553553
Principal investigator 1 ModernaTX, Inc. $25,905.36 04/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001723
Principal investigator 1 ModernaTX, Inc. $6,947.82 04/28/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001755
Principal investigator 1 SANOFI PASTEUR INC. $13,446.72 04/28/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108419
Principal investigator 1 SANOFI PASTEUR INC. $548,680.90 04/28/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108425
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $12,597.89 04/24/2025 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187890904
Principal investigator 1 SANOFI PASTEUR INC. $600.00 04/24/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226108408
Principal investigator 1 SANOFI PASTEUR INC. $600.00 04/24/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108414
Principal investigator 1 Janssen Research & Development, LLC $4,009.00 04/23/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192866
Principal investigator 1 ModernaTX, Inc. $26,453.41 04/18/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990118
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 04/17/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192748
Principal investigator 1 Janssen Research & Development, LLC $2,816.00 04/17/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192841
Principal investigator 1 GlaxoSmithKline, LLC. $450.00 04/04/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192113194
Principal investigator 1 ABBVIE INC. $574.77 04/03/2025 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202472727
Principal investigator 1 GlaxoSmithKline, LLC. $1,787.27 04/02/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH - DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192174289
Principal investigator 1 ModernaTX, Inc. $25,079.60 04/01/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001743
Principal investigator 1 SANOFI PASTEUR INC. $88.32 04/01/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108367
Principal investigator 1 SANOFI PASTEUR INC. $1,152.30 04/01/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108378
Principal investigator 1 GlaxoSmithKline, LLC. $3,897.81 03/26/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192113198
Principal investigator 1 Janssen Research & Development, LLC $4,010.00 03/24/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192902
Principal investigator 1 ModernaTX, Inc. $6,048.24 03/24/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001773
Principal investigator 1 ModernaTX, Inc. $31,699.98 03/24/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001801
Principal investigator 1 ModernaTX, Inc. $19,068.48 03/24/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001823
Principal investigator 1 Janssen Research & Development, LLC $1,076.00 03/21/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192831
Principal investigator 1 SANOFI PASTEUR INC. $19,800.00 03/21/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226108362
Principal investigator 1 SANOFI PASTEUR INC. $64,000.26 03/21/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108371
Principal investigator 1 SANOFI PASTEUR INC. $1,200.00 03/20/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108357
Principal investigator 1 GlaxoSmithKline, LLC. $185.54 03/18/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND-DELA
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192113934
Principal investigator 1 SANOFI PASTEUR INC. $140,819.34 03/11/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108353
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 03/05/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718103
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 03/05/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718105
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 03/05/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718107
Principal investigator 1 Boehringer Ingelheim International GmbH $615.00 03/05/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718109
Principal investigator 1 ModernaTX, Inc. $7,024.38 02/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001775
Principal investigator 1 ModernaTX, Inc. $55,693.60 02/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001793
Principal investigator 1 ModernaTX, Inc. $3,866.28 02/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001811
Principal investigator 1 ModernaTX, Inc. $26,246.22 02/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001817
Principal investigator 1 GlaxoSmithKline, LLC. $8,330.24 02/24/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192113206
Principal investigator 1 ABBVIE INC. $122.32 02/20/2025 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202452762
Principal investigator 1 ABBVIE INC. $343.33 02/20/2025 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202452767
Principal investigator 1 Janssen Research & Development, LLC $1,623.00 02/19/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192778
Principal investigator 1 Janssen Research & Development, LLC $2,931.00 02/19/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192885
Principal investigator 1 ModernaTX, Inc. $1,700.64 02/19/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001833
Principal investigator 1 Eli Lilly and Company $28,763.40 02/18/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1187892472
Principal investigator 1 SANOFI PASTEUR INC. $3,314.76 02/17/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108705
Principal investigator 1 Boehringer Ingelheim International GmbH $2,488.14 02/14/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718093
Principal investigator 1 Boehringer Ingelheim International GmbH $3,956.46 02/14/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718095
Principal investigator 1 Boehringer Ingelheim International GmbH $4,485.00 02/14/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718097
Principal investigator 1 Boehringer Ingelheim International GmbH $3,099.48 02/14/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718099
Principal investigator 1 Boehringer Ingelheim International GmbH $4,887.96 02/14/2025 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220718101
Principal investigator 1 Janssen Research & Development, LLC $20.00 02/14/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192719
Principal investigator 1 SANOFI PASTEUR INC. $600.00 02/12/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226108699
Principal investigator 1 SANOFI PASTEUR INC. $2,162.46 02/10/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108692
Principal investigator 1 ABBVIE INC. $1,199.45 02/06/2025 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202446907
Principal investigator 1 SANOFI PASTEUR INC. $169.20 02/03/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108674
Principal investigator 1 SANOFI PASTEUR INC. $42,288.72 02/03/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226108680
Principal investigator 1 Janssen Research & Development, LLC $895.00 01/31/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175333453
Principal investigator 1 ModernaTX, Inc. $1,950.00 01/30/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001781
Principal investigator 1 ModernaTX, Inc. $2,000.00 01/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990116
Principal investigator 1 ModernaTX, Inc. $54,530.15 01/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990124
Principal investigator 1 ModernaTX, Inc. $12,952.71 01/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252990126
Principal investigator 1 ModernaTX, Inc. $16,076.61 01/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001717
Principal investigator 1 ModernaTX, Inc. $2,500.00 01/29/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253001745
Principal investigator 1 SANOFI PASTEUR INC. $83,233.32 01/29/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108723
Principal investigator 1 SANOFI PASTEUR INC. $15,280.00 01/28/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108718
Principal investigator 1 Eli Lilly and Company $505.22 01/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1187890744
Principal investigator 1 ModernaTX, Inc. $9,971.94 01/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001741
Principal investigator 1 ModernaTX, Inc. $42,948.36 01/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001759
Principal investigator 1 ModernaTX, Inc. $59,564.05 01/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001777
Principal investigator 1 ModernaTX, Inc. $102,635.72 01/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001783
Principal investigator 1 ModernaTX, Inc. $16,039.32 01/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001799
Principal investigator 1 ModernaTX, Inc. $95,342.40 01/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001815
Principal investigator 1 ModernaTX, Inc. $10,442.55 01/27/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001819
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $169,889.85 01/24/2025 Non-covered Recipient Entity
ACCEL RESEARCH DELAND
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124034
Principal investigator 1 Janssen Research & Development, LLC $1,586.00 01/22/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175192825
Principal investigator 1 SANOFI PASTEUR INC. $204.45 01/22/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226108712
Principal investigator 1 Janssen Research & Development, LLC $3,890.00 01/21/2025 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175192856
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,084.00 01/17/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185553557
Principal investigator 1 ModernaTX, Inc. $149.67 01/16/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1253001809
Principal investigator 1 GlaxoSmithKline, LLC. $11,693.42 01/09/2025 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174300
Principal investigator 1 SANOFI PASTEUR INC. $43,943.34 01/07/2025 Non-covered Recipient Entity
University Clinical Research Dela Llc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226108687
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $451,283.54 01/01/2025 Non-covered Recipient Entity
ACCEL RESEARCH DELAND
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123466
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $143,156.11 01/01/2025 Non-covered Recipient Entity
ACCEL RESEARCH DELAND
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123736